ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / LMRI
CSTL (62) TRUP (63) FRNM (31) ALHC (56) ⌘ Pro Terminal →

Lumexa Imaging Holdings Inc. (LMRI) — RQD Stock Rating Cockpit

$11.15 -2.28% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $11.08

Lumexa Imaging Holdings Inc. (LMRI) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $1.10B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on LMRI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is LMRI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Lumexa Imaging Holdings Inc. (NASDAQ: LMRI) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $11.15 (-2.28% 1D, market cap $1.10B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, LMRI ranks #232 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does LMRI compare to CSTL and TRUP in the Health Care sector?
▼

Within the Health Care sector (Medical Specialities), LMRI carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CSTL (Castle Biosciences Inc.) holds a C grade (62/100 RQD, P/E N/A, ROIC -9.3%, cap $1.14B) and TRUP (Trupanion Inc.) posts a C grade (63/100 RQD, P/E 68.2x, ROIC 3.1%, cap $1.32B). Among the 5-stock peer group, TRUP leads on earnings multiple (68.2x) while ALHC leads on capital efficiency (13.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for LMRI?
▼

Per LMRI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002071288), Lumexa Imaging Holdings Inc. generated $741.1M in revenue, $0 in net income, and $0 in free cash flow against $1.76B in total assets and $819.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $11.08 (-0.60%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 11/20 (D+) • 4.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY • 50.6% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510053
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Cash (11)Whales (10)SEC (13)Macro (10)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-2.2% Base Target
$20 Bull$11 Base$9 Bear
📬 FREE LMRI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LMRI)Realized 20D OHLCV Swing Band: ±8.5%
Deterministic 5-Pillar Attribution (53/100 Composite)
🔍 WHY LMRI SCORES 53/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+11/20 pts (21% of score)

SEC XBRL FY 2025 (10-K): 4.1% FCF Margin ($30.7M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
45
Grade D$10.61+0.7% Next Q
Q2 (-2Q)
48
Grade D$10.68+9.3% Next Q
Q3 (-1Q)
50
Grade C-$11.67-4.5% Next Q
Current
53
Grade D+$11.15-0.9% Hist 90D α
Trajectory: D (45) → D+ (53)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a LMRI Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While LMRI currently carries a cautious 53/100 (D+) rating due to Insider Conviction & Share Dilution (9/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.09) and Max Pain ($11.71) forces dealer call-delta covering toward $20.42.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $LMRI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LMRI Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 53%NO 47%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
55.330 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE36% OF RANGE
L: $6$11.15H: $19
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: D+RQD 11 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: DRQD 19 / 40
3. Hidden Risks & Market Weather● WATCH
SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 23 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on LMRI

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (55)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (48)

19/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like LMRI
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LMRI)

  • ✓Walkthrough of LMRI's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
LMRI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +9.42%📐 HORIZONTAL RANGE
2026-11-03O $11.73H $11.73L $11.15C $11.15VOL 244.5K
RES: $11.97SUP: $9.82SMA50: $11.09SMA200: $11.06
$13.83$11.83$9.83$7.83$5.83RES $11.97SUP $9.82$11.152026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

LMRI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 LMRI Butterfly Map → + Track LMRI →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on LMRI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for LMRI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LMRI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LMRI)

Health Care Rank #232 of 1015 ⚔️ CSTL vs LMRI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (LMRI vs. CSTL, TRUP, FRNM, ALHC)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Lumexa Imaging Holdings Inc. (LMRI) ranks #232 by composite RQD confidence (53/100, grade D+) and #345 by equity capitalization ($1.10B). Within this direct 5-issuer industry benchmark cohort, TRUP leads on earnings valuation at 68.2x trailing P/E, while ALHC leads on capital efficiency and profitability with 13.9% ROIC and — gross margin. TRUP currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with LMRI at 53/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
LMRI ACTIVE
Lumexa Imaging Holdings Inc.
D+ 53/100 — — — -2.28% $1.10B Benchmark Subject
CSTL
Castle Biosciences Inc.
C 62/100 — 79.4% -9.3% -5.97% $1.14B /cstl-vs-lmri →
TRUP
Trupanion Inc.
C 63/100 68.2x 16.1% 3.1% +2.06% $1.32B /trup-vs-lmri →
FRNM
Freenome Inc.
E 31/100 — — -3.4% -6.97% $1.34B /frnm-vs-lmri →
ALHC
Alignment Healthcare Inc.
D+ 56/100 — — 13.9% -3.71% $1.52B /alhc-vs-lmri →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002071288 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lumexa Imaging Holdings Inc. (LMRI) reported GAAP revenue of $741.1M , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, LMRI closed FY2025 with $1.76B in total assets against $819.0M in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $741.1M $0 — — $1.76B $819.0M

3. LMRI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is LMRI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Lumexa Imaging Holdings Inc. (NASDAQ: LMRI) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $11.15 (-2.28% 1D, market cap $1.10B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, LMRI ranks #232 in composite RQD confidence.

How does LMRI compare to CSTL and TRUP in the Health Care sector?

Within the Health Care sector (Medical Specialities), LMRI carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CSTL (Castle Biosciences Inc.) holds a C grade (62/100 RQD, P/E N/A, ROIC -9.3%, cap $1.14B) and TRUP (Trupanion Inc.) posts a C grade (63/100 RQD, P/E 68.2x, ROIC 3.1%, cap $1.32B). Among the 5-stock peer group, TRUP leads on earnings multiple (68.2x) while ALHC leads on capital efficiency (13.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for LMRI?

Per LMRI's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002071288), Lumexa Imaging Holdings Inc. generated $741.1M in revenue, $0 in net income, and $0 in free cash flow against $1.76B in total assets and $819.0M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is LMRI trading relative to its 50-day, 200-day, and 52-week technical levels?

LMRI last traded at $11.15 (-2.28% on volume of 293,753 shares), positioning the stock +0.54% above its 50-day simple moving average ($11.09) and +0.81% above its 200-day simple moving average ($11.06). Across its 52-week range of $6.45 to $19.45, LMRI sits at the 36.2% percentile with a 14-day RSI of 55.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±8.5% ($10.20 to $12.10).

Direct Sub-Reports: LMRI RQD Cockpit LMRI 12M Forecast LMRI Earnings & Move LMRI Dividends & DRIP LMRI Insiders & 13F LMRI Whale Options LMRI Profit Sankey LMRI News & Why
ROARABLE RATING BRIEF • RQD 53/100 (D+) ✓ SEC XBRL & RQD VERIFIED

LMRI — Lumexa Imaging Holdings Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Lumexa Imaging Holdings Inc. (LMRI) earns a live Roarable RQD composite score of 53/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $11.15 (-2.28% 1D, market capitalization $1.10B).

  • Fundamental Cash Engine (11/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (10/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of 1.40x.

2. Business Model, Unit Margins & SEC Financial Trajectory

And profile, Lumexa Imaging Holdings Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Medical Specialities industry. The source data identifies the company's products, customers, and revenue model only at the sector level.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Lumexa Imaging Holdings Inc. (LMRI) reported $741.1M in annual revenue and $0 in GAAP net income. Operating cash flow reached $0 and free cash flow totaled $0, backed by $1.76B in total assets against $819.0M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 53/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 10/20. With Fundamental Cash Engine at 11/20 and Institutional Whale Flow at 10/20, sustained execution supports upside toward the upper end of the $6.45 – $19.45 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The source data therefore does not map upstream suppliers, downstream customers, or sector co-dependencies for LMRI. Sector and industry classification (Health Care, Medical Specialities) is the only context available. Second-order bottlenecks cannot be identified from the provided data. Investors should note that the absence of mapped links is a data gap, not evidence that no dependencies exist.

  • Key Question #1: Can LMRI sustain or expand its — operating margin and — ROIC against Medical Specialities peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $741.1M and free cash flow of $0, how will capital allocation balance growth reinvestment against $819.0M in total debt?
  • Key Question #3: How sensitive is LMRI's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

LMRI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Lumexa Imaging Holdings Inc. (LMRI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to LMRI Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

LMRI Bull vs. Bear Conversation Board — What's Your Call at $11.15?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LMRI 🐻 33% BEARISH CONVICTION
1. Pick Your Side on LMRI:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
CA CashFlowKing RQD DEBATE OPENER • FCF Compounder Hunter 🐂 BULLISH 🎯 Target: $13.69 (+20.0%)
📌 Pinned Debate

Recent coverage and a headline on possible profitability within a year, with a Forensic Balance Sheet pillar score of 13 / 20 supportin

Long LMRI at $11.41 targeting $13.69. Recent coverage and a headline on possible profitability within a year, with a Forensic Balance Sheet pillar score of 13 / 20 supporting solvency.. Institutional whale score is 10/20 and the risk/reward vs. the $6.45 52-week low is skewed heavily in favor of bulls.

RetailWhale_TX 🐂 BULL

Both sides have a point here — LMRI's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $9.70 (-15.0%)
Spot @ $11.41

Zero reported FY 2025 revenue and operating income against $819.0M of debt, with ROIC and FCF yield both at 0%.

Here is the bear case nobody on the bull side wants to address on LMRI: Zero reported FY 2025 revenue and operating income against $819.0M of debt, with ROIC and FCF yield both at 0%.. At current EV/EBITDA multiples, even a small guidance miss in Medical Specialities triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%